876379-22-5

Basic information

• Product Name: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE
• Synonyms: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE;Benzyl (3S)-3-[(tert-butoxycarbonyl)amino]piperidine-1-carboxylate;-1-Cbz-3-Boc-Aminopiperidine
• CAS NO: 876379-22-5
• Molecular Formula: C₁₈H₂₆N₂O₄
• Molecular Weight: 334.41
• Mol File: 876379-22-5.mol

Chemical Properties

• Boiling Point: 471.9±44.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.25±0.20(Predicted)
• CAS DataBase Reference: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE(876379-22-5)
• EPA Substance Registry System: (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE(876379-22-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-37
• Hazardous Substances Data: 876379-22-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE is used as a protecting agent in the synthesis of pharmaceutical compounds. Its role is to shield the amine groups during the synthesis process, allowing for the selective reactions required to construct complex peptide and protein structures.
Used in Peptide Synthesis:
In the field of peptide synthesis, (S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE is employed as a protecting group for amine functions. This protection is crucial for the stepwise construction of peptides, as it prevents unwanted side reactions and ensures the correct formation of peptide bonds.
Used in Research and Development:
(S)-1-CBZ-3-N-BOC-AMINOPIPERIDINE is utilized in research and development settings, particularly in the field of organic chemistry and biochemistry. It serves as a valuable tool for scientists to explore new synthetic pathways and develop novel compounds with potential applications in medicine and biotechnology.

Upstream product

• 501-53-1 benzyl chloroformate 
• 216854-23-8 tert-butyl (S)-piperidin-3-yl-carbamate 

Downstream Products

• 876378-16-4 benzyl (3S)-3-aminopiperidine-1-carboxylate hydrochloride 
• 1361323-51-4 tert-butyl (S)-1-((S)-3,3-dimethyl-1-((S)-1-(4-nitrophenethyl)piperidin-3-ylamino)-1-oxobutan-2-ylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-73-7 (S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)-N-((S)-1-(4-nitrophenethyl)piperidin-3-yl)butanamide 
• 1361323-52-5 tert-butyl (S)-1-((S)-3,3-dimethyl-1-oxo-1-((S)-1-(4-(trifluoromethyl)phenethyl)piperidin-3-ylamino)butan-2-ylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-74-8 (S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)-N-((S)-1-(4-(trifluoromethyl)phenethyl)piperidin-3-yl)butanamide 
• 876461-55-1 (S)-benzyl 3-aminopiperidine-1-carboxylate hydrochloride 
• 1361322-97-5 (S)-benzyl 3-((S)-2-(tert-butoxycarbonylamino)-2-cyclohexylacetamido)piperidine-1-carboxylate 
• 1361322-98-6 (S)-benzyl 3-((S)-2-amino-2-cyclohexylacetamido)piperidine-1-carboxylate hydrochloride 
• 1361322-99-7 (S)-benzyl 3-((S)-2-((S)-2-(tert-butoxycarbonyl(methyl)amino)propanamido)-2-cyclohexylacetamido)piperidine-1-carboxylate 
• 1361323-00-3 tert-butyl (S)-1-((S)-1-cyclohexyl-2-oxo-2-((S)-piperidin-3-ylamino)ethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361322-49-7 (S)-N-((S)-2-((S)-1-benzylpiperidin-3-ylamino)-1-cyclohexyl-2-oxoethyl)-2-(methylamino)propanamide 
• 1361322-50-0 (S)-N-((S)-1-cyclohexyl-2-oxo-2-((S)-1-(3-phenylpropyl)piperidin-3-ylamino)ethyl)-2-(methylamino)propanamide 
• 1361323-01-4 tert-butyl (S)-1-((S)-2-((S)-1-benzoylpiperidin-3-ylamino)-1-cyclohexyl-2-oxoethylamino)-1-oxopropan-2-yl(methyl)carbamate 
• 1361323-02-5 tert-butyl (S)-1-((S)-1-cyclohexyl-2-oxo-2-((S)-1-(2-phenylacetyl)piperidin-3-ylamino)ethylamino)-1-oxopropan-2-yl(methyl)carbamate 

Relevant articles and documents

Discovery of DS34942424: An orally potent analgesic without mu opioid receptor agonist activity

We identified (5′S)-10′-fluoro-6′-methyl-5′,6′-dihydro-3′H-spiro[cyclopropane-1,4′-[2,6]diaza[2,5]methano[2,6]benzodiazonin]-7′(1′H)-one, 22b (DS34942424) with a unique and original bicyclic skeleton. 22b showed an orally potent analgesic in the acetic ac

BENZAMIDE DERIVATIVE

The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

QUINAZOLINEDIONE DERIVATIVE

The present invention relates to quinazolinedione derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

Discovery of aminopiperidine-based Smac mimetics as IAP antagonists

A series of structurally unique Smac mimetics that act as antagonists of inhibitor of apoptosis proteins (IAPs) has been discovered. While most previously described Smac mimetics contain the proline ring (or a similar cyclic motif) found in Smac, a key feature of the compounds described herein is that this ring has been removed. Despite this, compounds in this series potently bind to cIAP1 and elicit the expected phenotype of cIAP1 inhibition in cancer cells. Marked selectivity for cIAP1 over XIAP is observed for these compounds, which is attributed to a slight difference in the binding groove between the two proteins and the resulting steric interactions with the inhibitors. XIAP binding can be improved by constraining the inhibitor so that these unfavorable steric interactions are minimized.

HETEROCYCLIC TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.

THERAPEUTIC ISOXAZOLE COMPOUNDS

The invention provides a compound of formula I: wherein A1, A2, A3, R1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

AMIDE DERIVATIVE

The present invention relates to a compound of the formula (I) being useful as a renin inhibitor, or a pharmaceutically acceptable salt thereof. wherein R1a is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; R1b is an optionally substituted C1-6 alkoxy, etc.; R1c is a hydrogen atom, an optionally substituted C1-6 alkoxy, etc.; R2 is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and each is a group of the formula: -A-B (in which A is a single bond, -(CH2)sO-, - (CH2)sN(R4)CO-, etc., B is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.), etc.; R4 is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; s is 0, etc.; and n is 1, etc.

AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.